TrialRheumatology (Oxford, England)2023

A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome.

Darren Bentley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.